Search

Debdulal Chakraborty,1 Subhendu Boral,1 Tushar Kanti Sinha,1 Arnab Das,1 Angshuman Mukherjee,1 Saptorshi Majumdar,1 Ranabir Bhattacharya,2 Ritobroto Maitra3 1Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India; 2Department of MIS, Disha Eye Hospitals, Kolkata, West Bengal, India; 3Radical Health Tech, New Delhi, IndiaCorrespondence: Debdulal Chakraborty, Department of Vitreoretinal services; Disha Eye Hospitals, Kolkata, West Bengal, India, Tel +91 33 66360000, Email devdc@rediffmail.comPurpose: This study investigates the efficacy of transitioning patients with neovascular age-related macular degeneration (nAMD) from aflibercept (T1) to biosimilar ranibizumab (T2), an approach not previously documented in literature.Methods: In this multicenter observational study, patients over 50 years of age with nAMD were shifted from intravitreal aflibercept (IVI AFL) to biosimilar ranibizumab (B-RBZ) due to financial constraints. This study employed standardized ophthalmological methods to assess visual acuity (VA), central macular thickness (CMT), and subretinal and intraretinal fluid. Statistical analyses included paired t-tests, Wilcoxon signed-rank tests, and linear regression.Results: A total of 29 eyes (12 males and 17 females) were analyzed. Mean age was 72.55 ± 6.43 years. VA improved significantly during T1, with a mean increase from 55.0 ± 10.2 to 70.0 ± 8.5 ETDRS letters at the switch time point (p < 0.01), then a slight decrease to 62.3 ± 8.9 at 12 months (p < 0.05) was noted during T2. The mean CMT decreased notably from 400 ± 50 to 290 ± 45 μm at the switch. The final CMT at 12 months after switching to B-RBZ was 280 ± 40 μm (p < 0.01). There was a significant decrease in the retinal and intra retinal fluid during T1, followed by a gradual increase during T2. A significant correlation (p < 0.05) was noted between the presence of intraretinal fluid and increased injection frequency of B-RBZ.Conclusion: The s

Debdulal Chakraborty,1 Soumen Mondal,1 Subhendu Boral,1 Arnab Das,1 Tushar Kanti Sinha,1 Saptorshi Majumdar,1 Ranabir Bhattacharya,2 Ritobroto Maitra3 1Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India; 2Department of MIS, Disha Eye Hospitals, Kolkata, West Bengal, India; 3Radical Health Tech, New Delhi, IndiaCorrespondence: Debdulal Chakraborty, Department of Vitreoretinal services, Disha Eye Hospitals, Kolkata, West Bengal, India, Tel +91 33 66360000, Email devdc@rediffmail.comPurpose: To analyse outcomes of innovator ranibizumab (IRM) (Lucentis) and biosimilar ranibizumab (BRM) (Razumab) in Indian eyes with neovascular age-related macular degeneration (nAMD).Methods: Retrospective observational study in nAMD patients, who were treated with IRM or BRM (3 loading doses followed by pro re nata (PRN). Primary outcome measures were change in best corrected visual acuity (BCVA) and central macular thickness (CMT) along with safety analysis. Secondary outcomes measures were changes in the subretinal fluid (SRF) and intraretinal fluid (IRF).Results: Inclusion criteria were satisfied in 164 eyes (60.74%). A total of 87 eyes were treated with IRM, and 77 eyes received BRM. Baseline BCVA was 0.57± 0.27 logMAR in IRM group and 0.61± 0.25 in the BRM group. At 3, 6, 9, and 12 months BCVA was 0.27± 0.22 (p< 0.0001), 0.34± 0.23 (p< 0.0001), 0.39± 0.25 (p< 0.0001), and 12 months 0.41± 0.23 (p< 0.0001) in the IRM group and 0.24± 0.16 (p< 0.0001), 0.27± 0.16 (p< 0.0001), 0.34± 0.17 (p< 0.0001), 0.38± 0.18 (p< 0.0001) in the BRM group. Baseline CMT was 420.39± 54.45 μm in IRM group and 407.82± 53.07 μm in BRM group. At 3, 6, 9, and 12 months, CMT decreased to 258.28± 20.4 μm (p< 0.0001), 268.38± 19.5 μm (p< 0.0001), 269.51± 32.41 μm (p< 0.0001), and 278.28± 16.56 μm (p< 0.0001) in the IRM group and 258.84± 17.47 μm (p< 0.0001), 265.69± 17.29 μm (p< 0.0001), 273.64± 23.13 μm (p&